S10 Ep3: Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC
Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.